skip to primary navigationskip to content

Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

last modified Oct 05, 2016 03:46 PM
Amadeus Capital Partners, the global technology investor, has made an early-stage investment of £1.5 million in ideaSpace alumni Healx, a Cambridge based healthcare company that seeks new uses for existing drugs in the fight against rare diseases.
Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

Dr Tim Guilliams, Healx CEO

Healx, founded and based in Cambridge, operates in the fast-growing drug ‘repurposing’ sector. The company uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis, to identify novel drug applications for rare diseases that afflict some 350 million people worldwide. Their unique model engages directly with patient advocacy groups, allowing them to lead the way in personalised healthcare for rare diseases.

Hermann Hauser, Partner and co-Founder of Amadeus Capital Partners, said, “Healx has taken advances in machine learning, data mining and analytics and combined them with deep pharma and life sciences expertise to address a growing need in the healthcare sector. With huge pressure on R&D budgets, drug repositioning will be essential in the fight against rare diseases. With this investment, Healx will take up a leadership position in the drug repurposing sector, expected to be worth over $31 billion by 2020.”

Healx has a scalable technology platform which allows it to match potential treatments to rare conditions and patients. Thanks to its data mining approach, the company aims to complete its drug repurposing studies within six months, much faster than historical literature-based studies.

While there are around 8,000 rare diseases – disorders affecting fewer than 1 in 2,000 people in Europe – only about 500 have a cure. Many are linked to genetics and children account for some 75% of identified cases. Healx has won contracts from major medical foundations in the US and Europe to find drug candidates to treat conditions including childhood diseases, Barth syndrome and Fragile-X.

Sales of ‘orphan’ drugs designed to treat a specific rare condition have been growing following changes in regulation and tax incentives in the US, with the market forecast to reach $178 billion in 2020. However, as only a small proportion of the population is affected by a particular rare disease, the justification for investing large sums in clinical trials remains a barrier to innovation.

Tim Guilliams, Chief Executive, Healx, commented: “Studies into rare medical conditions have long failed to receive adequate funding. By repurposing existing drugs to combat rare diseases, Healx is able to find potential treatments at a fraction of the cost and in a much shorter timeframe than developing a new drug. With this investment, Healx will have the resources to expand our technology platform and accelerate our drug review process to find treatments to many more devastating illnesses.”

To read more information, click here.

RSS Feed Latest news

First IPO for FreeAgent Central

Nov 22, 2016

Cloud-based accounting software provider, FreeAgent Central have started trading as a public company on the London Stock Exchange's Alternative Investment Market (AIM)

Spectral Edge showcase their Eyeteq and Nighteq technology at the OTTtv World Summit

Nov 17, 2016

ideaSpace West members, Spectral Edge, have been receiving a lot of media attention recently after showcasing their image processing technology at the OTTtv World Summit on the 8th to 10th November, 2016 in London.

Blackboard Announces Acquisition of U.K. Based Fronteer

Oct 26, 2016

Blackboard Inc., a leading education technology company for teaching, learning and student engagement, today announced the acquisition of U.K. based Fronteer, including its flagship Ally product. Ally is designed to help institutions and instructors make course content more accessible for learners.

View all news